| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Shenzhen Kangtai Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.26 |
| 52 Week High | CN¥34.18 |
| 52 Week Low | CN¥12.93 |
| Beta | 0.93 |
| 11 Month Change | 35.26% |
| 3 Month Change | 16.90% |
| 1 Year Change | -35.45% |
| 33 Year Change | -74.93% |
| 5 Year Change | -64.13% |
| Change since IPO | 823.00% |
Recent News & Updates
Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%
Oct 13
Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden
Sep 25Recent updates
Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%
Oct 13Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden
Sep 25These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts
Sep 02Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up
Aug 13Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly
May 25Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations
May 03Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%
May 01Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion
Feb 27Shareholder Returns
| 300601 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.7% | 1.7% | 2.7% |
| 1Y | -35.5% | -10.5% | 4.6% |
Return vs Industry: 300601 underperformed the CN Biotechs industry which returned -10.5% over the past year.
Return vs Market: 300601 underperformed the CN Market which returned 4.6% over the past year.
Price Volatility
| 300601 volatility | |
|---|---|
| 300601 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in CN Market | 11.4% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300601's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300601's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,902 | Xiang Miao | www.biokangtai.com |
Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company’s products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, live attenuated varicella vaccine, and HIB conjugate vaccine.
Shenzhen Kangtai Biological Products Co., Ltd. Fundamentals Summary
| 300601 fundamental statistics | |
|---|---|
| Market cap | CN¥20.39b |
| Earnings (TTM) | CN¥516.21m |
| Revenue (TTM) | CN¥2.95b |
39.5x
P/E Ratio6.9x
P/S RatioIs 300601 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300601 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.95b |
| Cost of Revenue | CN¥653.85m |
| Gross Profit | CN¥2.30b |
| Other Expenses | CN¥1.78b |
| Earnings | CN¥516.21m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 26, 2024
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 77.83% |
| Net Profit Margin | 17.50% |
| Debt/Equity Ratio | 22.2% |
How did 300601 perform over the long term?
See historical performance and comparison